Dr. Alexander Spira Discusses Advances in Non-Small Cell Lung Cancer (NSCLC)

(1:16)

Physician Spotlight: Alex Spira, M.D., PhD, F.A.C.P., Medical Oncologist

(44)

Post-osimertinib landscape for NSCLC

(1:)

Alexander Spira, MD, PhD, FACP, on managing lung cancer patients in a community setting

(50)

ASCO 2022: Dr. Alexander I. Spira on KRYSTAL-1 for Patients with Advanced/Metastatic NSCLC

(6:14)

Developments and challenges in MET targeting for lung cancer

(1:50)

Alexander Spira, MD, PhD, FACP, on the recent approval of atezolizumab in SCLC

(34)

Alexander Spira, MD, PhD, FACP, on how Virginia Cancer Specialists is embracing value-based care

(33)

Is It Enough to Be Quiet and Still Inside?

(9:)

Time Is Never Actually Experienced

(12:56)

WHAT IS LIFE? #22 Tim Freke and Rupert Spira

(1:7:56)

Consciousness Beyond Brain Function | Neurosurgeon Dr. Eben Alexander

(1:6:29)

Are There Stages of Realization? - Rupert Spira

(9:)

A Brilliant explanation of the Eternal now.

(9:28)

Alexander Dugin, Liberal Democracy \u0026 Great Reset - Michael Millerman \u0026 Igor Kufayev in Conversation

(1:48:35)

Disagreeing With Rupert Spira | What Happens to Mind After \

(4:16)

Voyages 005 - 231 BC to the South Pacific by Rata and Maui

(25:19)

Immuno Forum Georgetown 2017 How Does Immunotherapy Work Spira

(15:31)

Dr. Spira on the POPLAR Study for NSCLC

(1:25)

First line treatment options for activating EGFR non-small cell lung Cancer | Dr. Alexander Spira

(58)

Post-progression analysis of MARIPOSA-2: amivantamab + chemo in EGFR+ NSCLC

(3:21)

Alexander Spira, MD, PhD, FACP, tells us the latest thinking regarding the PD-L1 biomarker

(45)

ctDNA as a biomarker for monitoring treatment response in pancreatic cancer

(1:8)

The evolving treatment landscape for NSCLC with EGFR exon 20 insertion mutations

(1:46)

The SKIPPirr Study: Dr. Spira Shares Insights at IASLC 2024 World Conference on Lung Cancer

(3:55)

Medical Stories - Lung Cancer KRAS: Courage Over Cancer

(24:10)

Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial

(12:)

Modernization of clinical trial eligibility criteria

(1:39)

Management of adverse events from datopotamab deruxtecan in NSCLC

(1:5)